<div><div>NKGen Biotech announced two financing-related updates. The company amended its forward purchase agreement with Meteora to extend the Valuation Date to December 31, 2026, with all other terms unchanged, preserving flexibility under its equity forward arrangement. Separately, NKGen and NKGen Operating Biotech amended a secured promissory note with AlpineBrook Capital GP I, adding $372,000 of funding and increasing the note’s principal to $26,507,106, with interest on the new tranche accruing from January 23, 2026. Together, these steps aim to enhance liquidity and financial flexibility for ongoing operations.Agreement 1: NKGen Biotech Signs Eighth Amendment to Forward Purchase Agreement With Meteora Capital Partners<ul><li>Agreement type: Eighth amendment to forward purchase agreement for OTC equity prepaid forward transactions</li><li>Counterparty: Meteora Capital Partners and affiliates</li><li>Signed / Effective: Jan 20 2026 / same</li><li>Duration / Termination: Through Dec 31 2026</li><li>Reason: Extend valuation date and maintain financing flexibility</li></ul>Agreement 2: NKGen Biotech Signs Second Amendment to Secured Promissory Note With AlpineBrook Capital GP I<ul><li>Agreement type: Second amendment to secured promissory note</li><li>Counterparty: AlpineBrook Capital GP I</li><li>Signed / Effective: Jan 23 2026 / same</li><li>Duration / Termination: Until note maturity</li><li>Reason: Provide additional near-term funding</li></ul>Original SEC Filing: NKGen Biotech, Inc. [ NKGN ] - 8-K - Jan. 26, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

NKGN

IBBQ

SBIO

ARKG

NKGen Biotech has announced two financing updates: an amendment to its forward purchase agreement with Meteora, extending the Valuation Date to December 31, 2026, and an amendment to a secured promissory note with AlpineBrook Capital, adding $372,000 in funding and increasing the principal to $26,507,106. These agreements aim to enhance the company's liquidity and financial flexibility for ongoing operations.

NKGen Biotech Signs Multiple Financing Agreements